|Articles|February 1, 2003
Irradiated Hope
Santa Monica, Calif. - With melanoma rates increasing 3 to 5 percent each year, dermatologists can glean some hope from recent study results that found Canvaxin, a therapeutic cancer vaccine, doubled survival rates for patients with advanced melanoma.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement














